Cheng Liu
President & Chief Executive Officer Eureka Therapeutics
Seminars
Tuesday 19th May 2026
Applying TCR Mimic Antibodies in T-Cell Therapy to Achieve Durable & Persistent Clinical Responses
2:30 pm
- Sharing developments in an ongoing phase 1 trial and key learnings from the clinic
- Explaining how TCR mimic armed T-cell therapy enables dual activation of CD4 and CD8 T-cells
- Discuss why CD4 engagement is critical for long-term efficacy
